Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-3475-866 | Other Identifier | MSD Protocol Number | |
| KEYNOTE-866 | Other Identifier | MSD | |
| 2080224790 | Registry Identifier | jRCT | |
| 2022-501970-20-00 | Registry Identifier | EU CT | |
| 194870 | Registry Identifier | JAPAC-CTI | |
| U1111-1282-6279 | Registry Identifier | UTN | |
| 2018-003808-39 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pembrolizumab + Gemcitabine + Cisplatin + Surgery | Experimental | Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab. |
|
| Placebo + Gemcitabine + Cisplatin + Surgery | Placebo Comparator | Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle |
|
| Measure | Description | Time Frame |
|---|---|---|
| Event-Free Survival (EFS) | EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery; failure to undergo RC surgery in participants with residual disease and any radiographical disease present; gross residual disease left behind at the time of surgery; local or distant recurrence based on investigator assessments and/or biopsy, or death due to any cause. | Up to approximately 60 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pathologic Complete Response (pCR) Rate | pCR rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blinded independent central review (BICR). | Up to approximately 72 months |
| Overall Survival (OS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scripps MD Anderson ( Site 0010) | La Jolla | California | 92037 | United States | ||
| Providence Saint John's Health Center ( Site 0075) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34008425 | Derived | Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. |
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blind
| Gemcitabine | Drug | Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle |
|
| Cisplatin | Drug | Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle |
|
| Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) | Procedure | Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines. |
|
| Placebo | Drug | Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle |
|
Overall survival is defined as the time from randomization to death due to any cause. |
| Up to approximately 72 months |
| Disease-Free Survival (DFS) | DFS is defined as the time from post-surgery baseline scan until the first occurrence of either local or distant recurrence as assessed by investigator by CT or MRI and/or computerized tomography (CT) or magnetic resonance imaging (MRI) and or biopsy or death from any cause. | From approximately 20 weeks up to approximately 72 months |
| Pathologic Downstaging (pDS) Rate | pDS rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \ | Up to approximately 72 months |
| Number of Participants Who Experienced an Adverse Event (AE) | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 72 months |
| Number of Participants Who Discontinued Study Treatment Due to an AE | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 12 months |
| Number of Participants Who Experienced Perioperative Complications | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 12 months |
| Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G) | The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108. | Baseline, Up to approximately 72 months |
| Change in Patient-Reported Outcomes from Baseline in Total Score of FACT-Bladder- (FACT-BI-Cys) | Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168. | Baseline, Up to approximately 72 months |
| Change in Patient-Reported Outcomes from Baseline in FACT-BI-Cys-Trial Outcome Index (TOI) | FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116. | Baseline, Up to approximately 72 months |
| Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS) | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. | Baseline, Up to approximately 72 months |
| Time to Deterioration (TTD) in the Total Score of FACT-G | The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score. | Up to approximately 72 months |
| TTD in EQ-5D-5L VAS | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS. | Up to approximately 72 months |
| Santa Monica |
| California |
| 90404 |
| United States |
| Georgetown University Medical Center ( Site 0022) | Washington D.C. | District of Columbia | 20007 | United States |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005) | Orlando | Florida | 32804 | United States |
| Parkview Cancer Institute ( Site 0077) | Fort Wayne | Indiana | 46845 | United States |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 0004) | Indianapolis | Indiana | 46202 | United States |
| Ochsner Medical Center ( Site 0049) | New Orleans | Louisiana | 70121 | United States |
| New England Cancer Specialists ( Site 0070) | Scarborough | Maine | 04074 | United States |
| UMass Memorial Medical Center ( Site 0051) | Worcester | Massachusetts | 01655 | United States |
| Henry Ford Hospital ( Site 0039) | Detroit | Michigan | 48202 | United States |
| Mercy Hospital Saint Louis ( Site 0064) | St Louis | Missouri | 63141 | United States |
| Morristown Medical Center ( Site 0015) | Morristown | New Jersey | 07960 | United States |
| UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045) | Albuquerque | New Mexico | 87106 | United States |
| New York University Perlmutter Cancer Center ( Site 0008) | New York | New York | 10016 | United States |
| University Hospitals Cleveland Medical Center ( Site 0038) | Cleveland | Ohio | 44106 | United States |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021) | Tulsa | Oklahoma | 74146 | United States |
| Portland VA Medical Center ( Site 0084) | Portland | Oregon | 97239 | United States |
| Allegheny General Hospital ( Site 0048) | Pittsburgh | Pennsylvania | 15212 | United States |
| MD Anderson Cancer Center ( Site 0063) | Houston | Texas | 77030 | United States |
| Central Texas Veterans Healthcare System ( Site 0057) | Temple | Texas | 76504 | United States |
| Inova Schar Cancer Institute ( Site 0007) | Fairfax | Virginia | 22031 | United States |
| Northwest Medical Specialties, PLLC ( Site 0061) | Puyallup | Washington | 98373 | United States |
| Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033) | Seattle | Washington | 98109 | United States |
| Charleston Area Medical Center ( Site 0023) | Charles Town | West Virginia | 25304 | United States |
| Mid North Coast Cancer Institute ( Site 1256) | Port Macquarie | New South Wales | 2444 | Australia |
| Southside Cancer Care Centre ( Site 1252) | Sydney | New South Wales | 2228 | Australia |
| Cairns Base Hospital ( Site 1257) | Cairns | Queensland | 4870 | Australia |
| Eastern Health ( Site 1255) | Box Hill | Victoria | 3128 | Australia |
| Peninsula Health Frankston Hospital ( Site 1258) | Frankston | Victoria | 3199 | Australia |
| UZ Brussel ( Site 0358) | Brussels | Bruxelles-Capitale, Region de | 1090 | Belgium |
| Jessa Ziekenhuis ( Site 0360) | Hasselt | Limburg | 3500 | Belgium |
| CHU UCL Namur Site de Godinne ( Site 0354) | Yvoir | Namur | 5530 | Belgium |
| O.L.V. Ziekenhuis Aalst ( Site 0356) | Aalst | Oost-Vlaanderen | 9300 | Belgium |
| AZ Maria Middelares Gent ( Site 0353) | Ghent | Oost-Vlaanderen | 9000 | Belgium |
| Tom Baker Cancer Centre ( Site 0100) | Calgary | Alberta | T2N 4N2 | Canada |
| Nova Scotia Health Authority ( Site 0109) | Halifax | Nova Scotia | B3H 1V7 | Canada |
| Kingston Health Sciences Centre ( Site 0103) | Kingston | Ontario | K7L 2V7 | Canada |
| Lakeridge Health ( Site 0104) | Oshawa | Ontario | L1G 2B9 | Canada |
| Sunnybrook Research Institute ( Site 0110) | Toronto | Ontario | M4N 3M5 | Canada |
| Princess Margaret Cancer Centre ( Site 0107) | Toronto | Ontario | M5G 2M9 | Canada |
| CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105) | Montreal | Quebec | H1T 2M4 | Canada |
| Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 | Québec | Quebec | G1J 1Z4 | Canada |
| Rigshospitalet University Hospital ( Site 0401) | Copenhagen | Capital Region | 2100 | Denmark |
| Herlev og Gentofte Hospital. ( Site 0402) | Herlev | Capital Region | 2730 | Denmark |
| Odense Universitetshospital ( Site 0403) | Odense | Region Syddanmark | 5000 | Denmark |
| CHU de Bordeaux- Hopital Saint Andre ( Site 0456) | Bordeaux | Aquitaine | 33075 | France |
| Centre Leon Berard ( Site 0465) | Lyon | Auvergne | 69373 | France |
| Centre Francois Baclesse ( Site 0459) | Caen | Calvados | 14075 | France |
| Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457) | Plérin | Cotes-d Armor | 22190 | France |
| Hopital Foch ( Site 0483) | Suresnes | Hauts-de-Seine | 92150 | France |
| CHU de Montpellier - Hopital Saint-Eloi ( Site 0469) | Montpellier | Languedoc-Roussillon | 34295 | France |
| Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453) | Angers | Maine-et-Loire | 49000 | France |
| Hopital Robert Schuman ( Site 0452) | Metz | Moselle | 57070 | France |
| Centre Jean Perrin ( Site 0460) | Clermont-Ferrand | Puy-de-Dome | 63011 | France |
| Clinique Victor Hugo ( Site 0463) | Le Mans | Sarthe | 72000 | France |
| CHU de Rouen ( Site 0493) | Rouen | Seine-Maritime | 76031 | France |
| Institut Sainte Catherine ( Site 0454) | Avignon | Vaucluse | 84918 | France |
| Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502) | Tübingen | Baden-Wurttemberg | 72076 | Germany |
| Universitaetsklinikum Erlangen ( Site 0505) | Erlangen | Bavaria | 91058 | Germany |
| Universitaetsklinikum Carl Gustav Carus ( Site 0519) | Dresden | Saxony | 01307 | Germany |
| Universitaetsklinikum Magdeburg A.o.R. ( Site 0516) | Magdeburg | Saxony-Anhalt | 39120 | Germany |
| Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512) | Lübeck | Schleswig-Holstein | 23538 | Germany |
| Charite Universitaetsmedizin Berlin ( Site 0515) | Berlin | 10117 | Germany |
| Vivantes Klinikum am Urban ( Site 0522) | Berlin | 10967 | Germany |
| Pecsi Tudomanyegyetem AOK ( Site 1009) | Pécs | Baranya | 7624 | Hungary |
| SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010) | Szeged | Csongrád megye | 6720 | Hungary |
| Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1002) | Szolnok | Jász-Nagykun-Szolnok | 5004 | Hungary |
| Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001) | Budapest | 1106 | Hungary |
| Debreceni Egyetem Klinikai Kozpont ( Site 1006) | Debrecen | 4032 | Hungary |
| Petz Aladar Megyei Oktato Korhaz ( Site 1012) | Győr | 9023 | Hungary |
| Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007) | Kaposvár | 7400 | Hungary |
| Cork University Hospital ( Site 0722) | Cork | T12 DC4A | Ireland |
| Tallaght University Hospital ( Site 0710) | Dublin | D24 DH74 | Ireland |
| University Hospital Waterford ( Site 0723) | Waterford | X91ER8E | Ireland |
| Ha Emek Medical Center ( Site 0808) | Afula | 1834111 | Israel |
| Soroka Medical Center ( Site 0806) | Beersheba | 8410101 | Israel |
| Rambam Health Care Campus-Oncology Division ( Site 0802) | Haifa | 3109601 | Israel |
| Shaare Zedek Medical Center ( Site 0809) | Jerusalem | 9103102 | Israel |
| Hadassah Ein Kerem Medical Center ( Site 0810) | Jerusalem | 9112001 | Israel |
| Meir Medical Center ( Site 0803) | Kfar Saba | 4428164 | Israel |
| Rabin Medical Center ( Site 0804) | Petah Tikva | 4941492 | Israel |
| Sheba Medical Center ( Site 0801) | Ramat Gan | 5265601 | Israel |
| Sourasky Medical Center ( Site 0807) | Tel Aviv | 6423906 | Israel |
| Yitzhak Shamir Medical Center ( Site 0805) | Ẕerifin | 7030001 | Israel |
| Policlinico Gemelli di Roma ( Site 0558) | Roma | Abruzzo | 00168 | Italy |
| Policlinico di Modena ( Site 0553) | Modena | Emilia-Romagna | 41124 | Italy |
| A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559) | Catania | 95123 | Italy |
| Istituto Nazionale Studio e Cura dei Tumori ( Site 0551) | Milan | 20133 | Italy |
| Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552) | Naples | 80131 | Italy |
| Fondazione Salvatore Maugeri IRCCS. ( Site 0554) | Pavia | 27100 | Italy |
| Azienda Ospedaliera San Camillo Forlanini ( Site 0560) | Roma | 00152 | Italy |
| Azienda Ospedaliera Santa Maria Terni ( Site 0557) | Terni | 05100 | Italy |
| Hirosaki University Hospital ( Site 1502) | Hirosaki | Aomori | 036-8563 | Japan |
| National Cancer Center Hospital East ( Site 1504) | Kashiwa | Chiba | 2778577 | Japan |
| Ehime University Hospital ( Site 1508) | Tōon | Ehime | 791-0295 | Japan |
| Sapporo Medical University Hospital ( Site 1501) | Sapporo | Hokkaido | 060-8543 | Japan |
| University of Tsukuba Hospital ( Site 1503) | Tsukuba | Ibaraki | 305-8576 | Japan |
| Yokosuka Kyosai Hospital ( Site 1509) | Yokosuka | Kanagawa | 238-8558 | Japan |
| Nara Medical University Hospital ( Site 1510) | Kashihara | Nara | 634-8522 | Japan |
| Saitama Medical University International Medical Center ( Site 1505) | Hidaka | Saitama | 350-1298 | Japan |
| Chiba Cancer Center ( Site 1506) | Chiba | 260-8717 | Japan |
| Harasanshin Hospital ( Site 1515) | Fukuoka | 812-0033 | Japan |
| Hiroshima City Hiroshima Citizens Hospital ( Site 1513) | Hiroshima | 730-8518 | Japan |
| Nagano Municipal Hospital ( Site 1516) | Nagano | 381-8551 | Japan |
| Osaka Metropolitan University Hospital ( Site 1512) | Osaka | 545-8586 | Japan |
| Tokushima University Hospital ( Site 1514) | Tokushima | 770-8503 | Japan |
| Tokyo Medical and Dental University Hospital ( Site 1517) | Tokyo | Japan |
| Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254) | Monterrey | Nuevo León | 66269 | Mexico |
| Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300) | Aguascalientes | 20010 | Mexico |
| Centro Estatal de Cancerologia de Chihuahua ( Site 0253) | Chihuahua City | 31000 | Mexico |
| Instituto Nacional de Cancerologia ( Site 0256) | Tlalpan | 14080 | Mexico |
| Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | 85-796 | Poland |
| Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062) | Wroclaw | Lower Silesian Voivodeship | 50-556 | Poland |
| Europejskie Centrum Zdrowia Otwock ( Site 1057) | Otwock | Masovian Voivodeship | 05-400 | Poland |
| Luxmed Onkologia sp. z o. o. ( Site 1051) | Warsaw | Masovian Voivodeship | 01-748 | Poland |
| Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1060) | Bielsko-Biala | Silesian Voivodeship | 43-300 | Poland |
| Clinic of Bashkortostan State Medical University ( Site 0869) | Ufa | Baskortostan, Respublika | 450081 | Russia |
| Ivanovo Regional Oncology Dispensary ( Site 0852) | Ivanovo | Ivanovo Oblast | 153040 | Russia |
| Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861) | Krasnoyarsk | Krasnoyarsk Krai | 660133 | Russia |
| Kursk Regional Clinical Oncology Dispensary ( Site 0854) | Kursk | Kursk Oblast | 305524 | Russia |
| FSBI ""United Hospital with Polyclinic"" of the Administrative Department of the President of the Ru | Moscow | Moscow | 119285 | Russia |
| Central Clinical Hospital with outpatient Clinic ( Site 0856) | Moscow | Moscow | 121359 | Russia |
| Bayandin Murmansk Regional Clinical Hospital ( Site 0859) | Murmansk | Murmansk Oblast | 183057 | Russia |
| Volga District Medical Center Federal Medical and Biological Agency ( Site 0857) | Nizhny Novgorod | Nizhny Novgorod Oblast | 603074 | Russia |
| Omsk Clinical Oncology Dispensary ( Site 0865) | Omsk | Omsk Oblast | 644013 | Russia |
| Leningrad Regional Oncology Center ( Site 0868) | Saint Petersburg | Sankt-Peterburg | 188663 | Russia |
| Clinical Hospital Saint Luka ( Site 0867) | Saint Petersburg | Sankt-Peterburg | 194044 | Russia |
| Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866) | Saratov | Saratov Oblast | 410012 | Russia |
| National Cancer Center ( Site 1354) | Goyang-si | Kyonggi-do | 10408 | South Korea |
| Seoul National University Bundang Hospital ( Site 1356) | Seongnam-si | Kyonggi-do | 13620 | South Korea |
| Korea University Anam Hospital ( Site 1351) | Seoul | 02841 | South Korea |
| Seoul National University Hospital ( Site 1352) | Seoul | 03080 | South Korea |
| Asan Medical Center ( Site 1355) | Seoul | 05505 | South Korea |
| Samsung Medical Center ( Site 1353) | Seoul | 06351 | South Korea |
| Hospital San Pedro de Alcantara ( Site 0654) | Cáceres | Extremadura | 10003 | Spain |
| H. de Gerona Dr. Josep Trueta ( Site 0651) | Girona | Gerona | 17007 | Spain |
| Hospital Universitario Ramon y Cajal ( Site 0660) | Madrid | Madrid, Comunidad de | 28034 | Spain |
| Hospital Universitario Quiron Madrid ( Site 0657) | Pozuelo de Alarcón | Madrid, Comunidad de | 28223 | Spain |
| Instituto Valenciano de Oncologia - IVO ( Site 0662) | Valencia | Valenciana, Comunitat | 46009 | Spain |
| Hospital del Mar ( Site 0653) | Barcelona | 08003 | Spain |
| Hospital Universitario San Carlos ( Site 0663) | Madrid | 28040 | Spain |
| Hospital Universitario La Paz ( Site 0661) | Madrid | 28046 | Spain |
| Hospital Nuestra Sra. de Valme ( Site 0658) | Seville | 41014 | Spain |
| Laenssjukhuset Ryhov ( Site 1205) | Jönköping | Jönköping County | 551 85 | Sweden |
| Akademiska Sjukhuset ( Site 1201) | Uppsala | Uppsala County | 751 85 | Sweden |
| Cancercentrum ( Site 1204) | Umeå | Västerbotten County | 901 85 | Sweden |
| Ramathibodi Hospital. ( Site 1451) | Bangkok | Bangkok | 10400 | Thailand |
| Faculty of Medicine Siriraj Hospital ( Site 1452) | Bangkok | Bangkok | 10700 | Thailand |
| Maharaj Nakorn Chiangmai Hospital ( Site 1453) | Chiang Mai | 50200 | Thailand |
| Srinagarind Hospital ( Site 1454) | Khon Kaen | 40002 | Thailand |
| Hacettepe Universitesi Tıp Fakultesi ( Site 0911) | Ankara | 06100 | Turkey (Türkiye) |
| Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0910) | Istanbul | 34096 | Turkey (Türkiye) |
| TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0906) | Istanbul | 34722 | Turkey (Türkiye) |
| Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0901) | Istanbul | 34899 | Turkey (Türkiye) |
| Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0909) | Konya | 42080 | Turkey (Türkiye) |
| Sakarya Universitesi Tip Fakultesi ( Site 0913) | Sakarya | 54290 | Turkey (Türkiye) |
| Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0904) | Trabzon | 61080 | Turkey (Türkiye) |
| Cherkasy Regional Oncology Dispensary ( Site 0959) | Cherkasy | Cherkasy Oblast | 18009 | Ukraine |
| Regional Oncological Hospital ( Site 0956) | Dnipro | Dnipropetrovsk Oblast | 49055 | Ukraine |
| Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 0951) | Dnipro | Dnipropetrovsk Oblast | 49102 | Ukraine |
| MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0963) | Dnipropetrovsk | Dnipropetrovsk Oblast | 49005 | Ukraine |
| Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 0969) | Kharkiv | Kharkiv Oblast | 61037 | Ukraine |
| CNPE "Regional Center of Oncology" ( Site 0958) | Kharkiv | Kharkiv Oblast | 61070 | Ukraine |
| National Cancer Institute of the MoH of Ukraine ( Site 0962) | Kyiv | Kyivska Oblast | 03022 | Ukraine |
| Lviv Regional Clinical Hospital ( Site 0955) | Lviv | Lviv Oblast | 79000 | Ukraine |
| Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0967) | Lviv | Lviv Oblast | 79000 | Ukraine |
| Kyiv City Clinical Oncology Center ( Site 0960) | Kyiv | 03115 | Ukraine |
| Aberdeen Royal Infirmary ( Site 0708) | Aberdeen | Aberdeen City | AB25 2ZN | United Kingdom |
| Torbay Hospital ( Site 0704) | Torquay | Devon | TQ2 7AA | United Kingdom |
| Kent and Canterbury Hospital ( Site 0709) | Canterbury | England | CT1 3NG | United Kingdom |
| Lister Hospital ( Site 0715) | Stevenage | Hertfordshire | SG1 4AB | United Kingdom |
| The Royal Marsden Foundation Trust ( Site 0702) | London | London, City of | SW3 6JJ | United Kingdom |
| Imperial College Healthcare NHS Trust ( Site 0721) | London | London, City of | W6 8RF | United Kingdom |
| Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 0725) | Norwich | Norfolk | NR4 7UY | United Kingdom |
| Royal Cornwall Hospital ( Site 0703) | Truro | TR1 3LJ | United Kingdom |
| Plain Language Summary | View source |
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| C565324 | Parkinson Disease 4, Autosomal Dominant Lewy Body |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582435 | pembrolizumab |
| D000093542 | Gemcitabine |
| D002945 | Cisplatin |
| D013514 | Surgical Procedures, Operative |
| D015653 | Cystectomy |
| ID | Term |
|---|---|
| D006571 | Heterocyclic Compounds |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D013520 | Urologic Surgical Procedures |
| D013519 | Urogenital Surgical Procedures |
Not provided
Not provided